Town Hall
Event Title
Virtual Town Hall - Test Development and Validation During the COVID-19 Public Health Emergency
April 26, 2023
- Date:
- April 26, 2023
- Time:
- 12:05 PM - 1:00 PM ET
Tell us what you think about the town halls
On This Page:
Summary:
On April 26, 2023, the U.S. Food and Drug Administration (FDA) will host a virtual town hall for test developers to discuss the Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency and Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19) final guidance documents. The guidances outline the FDA's general recommendations to transition from certain policies adopted and operations implemented during the COVID-19 pandemic to normal operations, including the FDA's recommendations for:
- Developing a transition implementation plan for in vitro diagnostics (IVDs) with an EUA,
- Submitting an IVD marketing submission,
- Taking other actions with respect to these IVDs, and
- Additional information related to test developers and COVID-19 tests.
No registration required.
You will have an opportunity to ask questions live during the virtual town hall and you may also submit questions in advance by emailing [email protected].
- Please submit questions by Monday 12 p.m. ET before the Wednesday virtual town hall.
- In the subject line of the email, type Questions for the Virtual Town Hall Test Development and Validation During Public Health Emergencies.
Save the Date:
The FDA will hold a virtual town hall on the following dates from 12:05 p.m.-1 p.m. ET:
- April 26: Ad Hoc Town Hall on recently finalized COVID-19 Transition Guidances for Medical Devices
Add this to my Calendar
Outlook users: Click link, select Open, then click Save & Close
Background:
The final transition guidances provide recommendations and clarity for medical device manufacturers that may or may not want to continue to distribute their devices after the relevant device EUA declaration related to COVID-19 under section 564 of the Federal Food, Drug, and Cosmetic Act terminates or the enforcement policies in certain COVID-19 device guidances are no longer in effect.
The FDA encourages stakeholders to review the two final guidances, attend the CDRH webinar on April 18, and reach out to the FDA if they have questions or concerns. In particular, for manufacturers planning to seek marketing authorization for their devices, the FDA recommends beginning work on a marketing submission, including a transition implementation plan, as described in the guidances.
- Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19)
- Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
Virtual Town Hall Details:
No registration required.
Time: 12:05 p.m. - 1 p.m. ET
To ensure you are connected, please join 15 minutes before the start of the virtual town hall.
Please click the link below to join the webinar:
Please note: Participants who join the virtual town hall using the Zoom webinar link above should use computer audio (listen through computer speakers and speak through computer microphone/headset to ask a question).
The dial-in information provided below is for participants who will be joining the virtual town hall by phone only.
U.S. Callers Dial: 833-568-8864 (Toll Free)
International Callers Dial: Please check the international numbers available
Webinar ID: 161 208 3563
Passcode: 728477
Following the virtual town hall, the presentation, printable slides (if applicable), and transcript, will be posted to CDRH Learn under the section In Vitro Diagnostics.
The presentation, printable slides (if applicable), and transcript from previous town halls are available for viewing on CDRH Learn under the section In Vitro Diagnostics.